Euthymics Bioscience’s Phase IIb/IIIa study of amitifadine has failed to produce positive results in treating major depressive disorder (MDD) at 50mg or 100mg doses.

The Triple Reuptake Inhibitor Anti-Depressant Effects (TRIADE) trial did not show a statistically significant difference in the primary endpoint of change in the Montgomery-Ã…sberg Depression Rating Scale compared to placebo.

Designed to assess the safety and efficacy of the serotonin-preferring triple reuptake inhibitor antidepressant, the study involved MDD patients who had failed to respond to first-line antidepressants.

However, supported by a lack of side effects with the 100mg dose and signs of efficacy in post-hoc analyses, an active comparator arm indicated that the drug could show efficacy at higher doses.

Massachusetts General Hospital Clinical Trials Network and Institute executive director and TRIADE principal investigator Dr Maurizio Fava said that given the robust efficacy of the comparator paroxetine in the study, amitifadine was under-dosed.

"However, supported by a lack of side effects with the 100mg dose and signs of efficacy in post-hoc analyses, an active comparator arm indicated that the drug could show efficacy at higher doses."

"However, the good tolerability of amitifadine allows for a significant dose escalation in the next study, aimed at replicating the positive findings of a previously conducted proof-of-concept study in patients with a new-onset major depressive episode," Fava said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Euthymics president and CEO Anthony McKinney said; "Amitifadine continues to have the potential to fulfil a critical unmet need among depression patients as one of the few monotherapy antidepressants for non-responders that has both a favorable sexual function and weight profile."

Amitifadine was well-tolerated at both the doses in the study without exhibiting any associated side-effects compared to paroxetine, which led to considerable sexual dysfunction.

The single molecule, which acts on serotonin, norepinephrine and dopamine, is also being studied as a treatment for alcohol abuse disorder.